Treatment of Behcet's Disease: An Algorithmic Multidisciplinary Approach

被引:45
作者
Alpsoy, Erkan [1 ]
Leccese, Pietro [2 ,3 ]
Emmi, Giacomo [4 ]
Ohno, Shigeaki [5 ,6 ]
机构
[1] Akdeniz Univ, Sch Med, Dept Dermatol & Venereol, Antalya, Turkey
[2] San Carlo Hosp Potenza, Rheumatol Dept Lucania, Rheumatol Inst Lucania, Potenza, Italy
[3] Madonna Grazie Hosp Matera, Matera, Italy
[4] Univ Firenze, Dept Expt & Clin Med, Florence, Italy
[5] Aishin Mem Hosp, Ophthalmol Ctr, Sapporo, Hokkaido, Japan
[6] Hokkaido Univ, Dept Ophthalmol, Fac Med, Grad Sch Med, Sapporo, Hokkaido, Japan
关键词
algorithms; therapeutics; morbidity; mortality; Behç et' s disease; ANTI-TNF-ALPHA; PULMONARY-ARTERY INVOLVEMENT; DAGGER-ETS DISEASE; DOUBLE-BLIND TRIAL; CYCLOSPORINE-A; INTESTINAL INVOLVEMENT; MUCOCUTANEOUS LESIONS; CLINICAL-FEATURES; APHTHOUS ULCERS; OCULAR LESIONS;
D O I
10.3389/fmed.2021.624795
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Behcet's disease (BD) is a chronic, relapsing inflammatory, multisystem disease of unknown etiology. The disease has a wide clinical spectrum of mucocutaneous lesions and ocular, vascular, articular, neurologic, gastrointestinal and cardiac involvement. Although the number of effective drugs used in the disease's treatment has increased in recent years, BD is still associated with severe morbidity because of mainly mucocutaneous, articular and ocular symptoms and an increased mortality because of large vessel, neurological, gastrointestinal and cardiac involvement. Many factors are associated with a more serious course, such as male gender and a younger age of onset. While the severity of the disease is more pronounced in the first years of the disease, it decreases in most patients after the age of forties. The primary goal of treatment should be the prevention of irreversible organ damage. Therefore, early diagnosis and appropriate treatment and close follow-up are mandatory to reduce the morbidity and mortality of the disease. Treatment varies depending on the organ involved and the severity of the involvement. For all these reasons, the treatment should be personalized and arranged with a multidisciplinary approach according to the organs involved. Treatment is mainly based on suppression of the inflammatory attacks of the disease using local and systemic immunomodulatory and immunosuppressive drugs. In this review, based on the mainly controlled studies and personal experience in clinical practice and basic research in this field, we propose a stepwise, symptom-based, algorithmic approach for the management of BD with a holistic perspective.
引用
收藏
页数:11
相关论文
共 109 条
  • [1] Ocular Behcet's Disease: Changing Patterns Over Time, Complications and Long-Term Visual Prognosis
    Accorinti, Massimo
    Pesci, Francesca Romana
    Pirraglia, Maria Pia
    Abicca, Irene
    Pivetti-Pezzi, Paola
    [J]. OCULAR IMMUNOLOGY AND INFLAMMATION, 2017, 25 (01) : 29 - 36
  • [2] Tocilizumab for severe refractory neuro-Behcet: Three cases IL-6 blockade in neuro-Behcet
    Addimanda, Olga
    Pipitone, Nicolo
    Pazzola, Giulia
    Salvarani, Carlo
    [J]. SEMINARS IN ARTHRITIS AND RHEUMATISM, 2015, 44 (04) : 472 - 475
  • [3] AKTULGA E, 1980, HAEMATOLOGICA, V65, P399
  • [4] Clinical features and natural course of Behcet's disease in 661 cases: a multicentre study
    Alpsoy, E.
    Donmez, L.
    Onder, M.
    Gunasti, S.
    Usta, A.
    Karincaoglu, Y.
    Kandi, B.
    Buyukkara, S.
    Keseroglu, O.
    Uzun, S.
    Tursen, U.
    Seyhan, M.
    Akman, A.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2007, 157 (05) : 901 - 906
  • [5] INTERFERON THERAPY FOR BEHCETS-DISEASE
    ALPSOY, E
    YILMAZ, E
    BASARAN, E
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1994, 31 (04) : 617 - 619
  • [6] Alpsoy E, 2005, CLIN EXP RHEUMATOL, V23, P532
  • [7] The use of sucralfate suspension in the treatment of oral and genital ulceration of Behcet disease - A randomized, placebo-controlled, double-blind study
    Alpsoy, E
    Er, H
    Durusoy, C
    Yilmaz, E
    [J]. ARCHIVES OF DERMATOLOGY, 1999, 135 (05) : 529 - 532
  • [8] Serum of patients with Behcet's disease induces classical (pro-inflammatory) activation of human macrophages in vitro
    Alpsoy, E
    Kodelja, V
    Goerdt, S
    Orfanos, CE
    Zouboulis, CC
    [J]. DERMATOLOGY, 2003, 206 (03) : 225 - 232
  • [9] Interferon alfa-2a in the treatment of Behcet disease - A randomized placebo-controlled and double-blind study
    Alpsoy, E
    Durusoy, C
    Yilmaz, E
    Ozgurel, Y
    Ermis, O
    Yazar, S
    Basaran, E
    [J]. ARCHIVES OF DERMATOLOGY, 2002, 138 (04) : 467 - 471
  • [10] A randomized, controlled and blinded study of papulopustular lesions in Turkish Behcet's patients
    Alpsoy, E
    Aktekin, M
    Er, H
    Durusoy, C
    Yilmaz, E
    [J]. INTERNATIONAL JOURNAL OF DERMATOLOGY, 1998, 37 (11) : 839 - 842